Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8:38:100872.
doi: 10.1016/j.lanepe.2024.100872. eCollection 2024 Mar.

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023

Katherina Aguilera  1 , Oscar Bladh  1 , Ulrika Marking  1   2 , Nina Greilert Norin  1 , Ali Rihani  3 , Dorina Ujvari  3 , Frank Chenfei Ning  3 , Jonas Klingström  2   4 , Sebastian Havervall  1 , Mikael Åberg  5 , Kim Blom  1   2 , Jessica J Alm  3 , Charlotte Thålin  1
Affiliations

Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023

Katherina Aguilera et al. Lancet Reg Health Eur. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Prevalence, viral load, and viral variants among Swedish healthcare workers on duty in December 2023. A) Percentage positive per day during December 4–15, 2023. Bars show total number of tested participants per day; grey = negative; black = positive. Numbers above bar depict percent positive. B) Individual Ct-values (SARS CoV-2 N-gene) for each positive sample as an indication of viral load. C) Viral variant identification by whole genome sequencing in each positive sample December 4–15, 2023. Bars show total number of diagnosed infections per day, and their individual variants JN.1, JN.2, JN.3, JN.8, BA.2.86.1 and XBB.1. Ct; Cyclic threshold, NA; Not available.
See this image and copyright information in PMC

References

    1. Control ECfDPa SARS-CoV-2 variants of concern as of 15 December 2023. 2023. https://www.ecdc.europa.eu/en/covid-19/variants-concern
    1. Miller J., Hachmann N.P., Collier A.-R.Y., et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388(7):662–664. doi: 10.1056/NEJMc2214314. - DOI - PMC - PubMed
    1. Link-Gelles R., Ciesla A.A., Fleming-Dutra K.E., et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(1526–1530):1526–1530. doi: 10.15585/mmwr.mm7148e1. - DOI - PMC - PubMed
    1. Marking U., Bladh O., Aguilera K., et al. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster. BioRxiv. 2023 doi: 10.1101/2023.12.21.572575. - DOI - PubMed
    1. Stankov M.V., Hoffmann M., Gutierrez Jauregui R., et al. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. Lancet Infect Dis. 2024;24(1):e1–e3. doi: 10.1016/S1473-3099(23)00690-4. - DOI - PubMed